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ABSTRACT 
Objectives: To describe the clinical features, genotype, and treatment of a 
series of subjects with confirmed Deficiency of Adenosine Deaminase 2 (DADA2) 
referred to Great Ormond Street Hospital NHS Foundation Trust (GOSH), 
London.  
Methods All symptomatic subjects were referred for genetic testing for 
suspected DADA2; relatives of index cases were also screened. The 
demographic, clinical, laboratory characteristics and treatments were recorded. 
Genetic analyses performed included whole-exome sequencing in 4 patients; 
and Sanger sequencing of Cat Eye Syndrome Chromosome Region Candidate 1 
(CECR1) in all subjects. ADA2 enzyme activity assay, and quantitative PCR of 
CECR1 mRNA were also performed.   
Results We identified 15 subjects with DADA2; 5 subjects were asymptomatic 
(relatives of index cases; age 5-42 years). Homozygous or compound 
heterozygous mutations in CECR1 were identified in all subjects. The phenotypic 
manifestations of the symptomatic DADA2 patients included livedo racemosa 
(73.3%); neurologic involvement (53.3%); and immune deficiency (46.6%). 
CECR1 mRNA expression in 8 subjects, including five pre-symptomatic subjects 
was significantly lower than healthy controls (p=0.0016). DADA2 subjects (with or 
without symptoms) also had lower ADA2 enzyme activity compared to healthy 
paediatric controls (p<0.0001), and sporadic cases of childhood polyarteritis 
nodosa without CECR1 mutation (p=0.0108). Nine/10 symptomatic patients 
required anti-TNF-α therapy. 
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Conclusion The clinical severity of DADA2 ranged from limited cutaneous to 
severe multi-systemic vasculitis; one third (5/15) of our cases were currently 
asymptomatic, and required close monitoring. We recommend CECR1 screening 
for: unaffected siblings of index cases; cases of familial vasculitis; and patients 
with polyarteritis nodosa recalcitrant to standard treatment.  
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INTRODUCTION 
Loss of function mutations in the Cat Eye Syndrome Chromosome Region 
Candidate 1 (CECR1) gene cause Deficiency of Adenosine Deaminase 2 
(DADA2) in patients with vasculopathy and clinical features compatible with 
polyarteritis nodosa (PAN) (1,2), a necrotizing medium vessel vasculitis (3). 
Clinical features of DADA2 frequently described in these first reports were 
positive family history, livedo racemosa, early-onset stroke, peripheral nervous 
system involvement, and immunodeficiency in some cases (1,2). The true 
breadth of the phenotype of DADA2 remains to be fully established. Another 
increasingly controversial issue regards the management of pre-symptomatic 
individuals with DADA2 detected as a result of family screening following 
identification of an index case. The purpose of this study was therefore to 
describe the clinical features, genotype, and treatment of a case series of 
subjects with confirmed DADA2 referred to a tertiary vasculitis referral centre, 
Great Ormond Street Hospital NHS Foundation Trust (GOSH), United Kingdom.  
 
PATIENTS AND METHODS 
 
Patients and controls 
This study was approved by the Bloomsbury research ethics committee, London 
(REC reference 08/H0713/82); all subjects studied prior to publication of the 
initial reports of DADA2 provided fully-informed written consent to participate, 
and informed assent where appropriate. Following publication of the original 
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DADA2 reports, some subjects had CECR1 screening as part of routine clinical 
care. Inclusion criteria were: 1. children and their relatives referred for genetic 
testing for suspected DADA2; and 2. availability of DNA for study purposes. Data 
recorded at the time of diagnosis were: sex, age, ethnicity, organ involvement, 
the serum C-reactive protein (CRP) level, histopathologic and arteriographic 
findings, and treatment.  
 
We also performed functional analyses on samples from patients and their 
relatives whenever possible. Healthy reference ranges for adenosine deaminase 
2 (ADA2) enzyme activity (see methods below) were derived from left over 
samples (n=22) from healthy paediatric patients for development of diagnostic 
tests for primary immunodeficiency (REC reference 06/Q0508/16). Reference 
ranges for healthy adults were derived from samples from healthy volunteer adult 
donors working in our laboratory (n=20), with consent. Sporadic childhood PAN 
(cPAN) patients without CECR1 mutations served as disease controls for ADA2 
enzyme activity. In addition, CECR1 mRNA expression was evaluated in 7 
paediatric and 1 adult patient with DADA2 (Table 1); 2 healthy child controls 
(different individuals from the controls used for ADA2 enzyme activity, with 
consent); and 4 healthy adults (who also had ADA2 enzyme activity assessed).                                                                 
 
Genetic analyses  
Whole-exome sequencing (WES) was performed in four patients where there 
was a strong clinical suspicion (familial cases; and/or onset in infancy) of a 
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monogenic cause for their vasculitis prior to the publication of the original 
descriptions of DADA2 (1,2). Other symptomatic cases were detected by Sanger 
sequencing of CECR1 in patients with cPAN resistant to standard treatment. 
Confirmation by Sanger sequencing of CECR1 was performed in all subjects, 
including those who initially underwent WES. Homozygosity mapping was also 
performed in one patient from consanguineous parents (family A). Library 
preparation for WES was completed using the Illumina Nextera Rapid Capture 
Exome Library Preparation Kit. WES was completed using the Illumina HiSeq 
1000 and Illumina NextSeq 500 platform. Sanger sequencing was performed 
using the Applied Biosystems 3730 DNA Analyzer; see Supplemental Table S-1. 
 
Quantitative PCR 
RNA was obtained from peripheral blood samples collected in PAXgene blood 
RNA tubes (Qiagen). RNA isolation was performed using the PAXgene blood 
RNA kit (Qiagen). Complementary DNA synthesis was performed using High-
Capacity RNA-to-cDNA kit (Lifetechnologies). Quantitiative PCR (qPCR) was 
performed using Power SYBR green PCR mastermix (Lifetechnologies) with 
specific primers for CECR1 (QIAGEN: QT01667862) to analyse gene 
expression. β-actin was used as a reference gene. The qPCR was performed on 
the real time PCR system (Rotor-gene 6000). Analysis was done on the Rotor-
gene 6000 Series software version 1.7, using the standard curve method for the 
quantification. Samples from each case were tested once. 
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ADA2 enzyme activity assay  
Adenosine deaminase assay kit (Diazyme) was used to quantify ADA2 enzyme 
activity, as per manufacturer instructions (see supplemental methods). 100nM of 
erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), an specific adenosine deaminase 
1 (ADA1) inhibitor, was added during the assay. Light absorbance at wavelength 
540nm as a measure of ADA2 activity was assessed using a Fluorstar Optima 
spectrophometer. Samples from each case were tested once; the intra-test 
coefficient of variation (CV) for this assay is < 4.5%, and inter-test CV is < 5% 
(manufacturer’s product sheet). 
 
 
Statistical Analysis  
Continuous variables were summarized as median and range. Categorical 
variables were presented as percentages and frequencies. Comparison of ADA2 
enzyme activity and mRNA expression were performed using the Mann-Whitney 
U test. A p-value (two-tailed) of <0.05 was considered significant. All statistical 
tests were performed using GraphPad Prism version 5. 
 
RESULTS 
 
Demographic and clinical features of DADA2 patients 
We identified 15 subjects with DADA2, confirmed with Sanger sequencing. Of 
these 15 subjects, 13 were seen at GOSH; 2 patients (siblings) were seen at 
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Queen Silvia’s Children Hospital, Sweden. The clinical features of all the 
genetically confirmed DADA2 subjects are shown in Table 1. Five of the 15 
subjects were asymptomatic (including patient C2, Table 1, who was 
asymptomatic, but had mild livedo racemosa detected on a screening clinical 
examination), and were relatives of index cases.  
 
A family history of symptoms compatible with DADA2 was positive in 3 families. 
Two patients included in this series were born to related Iraqi/Iranian patients 
(family A); 2 patients were born to unrelated Indian parents (family B); and 2 
patients were born to unrelated Caucasian Swedish parents (family G). In 
addition, regarding family G, the mother was noted to have a bicuspid aortic 
valve, and developed an aneurysm of the thoracic arch of aorta requiring surgical 
intervention. The pedigree of family A is shown in figure 1A; and pedigrees for 
families B, C and G are provided as supplementary material. Eleven/15 (73.3%) 
patients had livedo racemosa. Neurologic manifestations were present in 8/15 
patients (53.3%); central nervous system (CNS) involvement in 6 patients; and 
peripheral nervous system (PNS) involvement in 2 patients. Renovascular 
involvement was present in 3 patients (patients D, E and F), with renal arterial 
aneurysms and other features of medium vessel vasculitis demonstrated on 
catheter arteriography (Figure 1B and see below). Seven/15 (46.6%) subjects 
had immune deficiency: lymphopenia in 6/7 patients; and low immunoglobulin in 
6/7 patients, 2 of whom required immunoglobulin replacement (Table 1). 
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Histopathological and angiographic findings 
Six/10 of the symptomatic DADA2 patients had tissue biopsy performed 
(Supplemental Table S-2). This revealed evidence of vasculitis in 4/6. Eight 
patients had at least one mode of angiography performed (catheter digital 
subtraction arteriography, magnetic resonance angiogram, or computed 
tomography angiography). This was suggestive of vasculitis/vasculopathy in 7/8 
patients (Supplemental Table S-2). 
 
Treatment 
Nine/10 patients required active treatment with anti-TNF-α, with or without daily 
prednisolone and/ or an alternative disease modifying anti-rheumatic drug 
(DMARD; Table 1). The indication for use of anti-TNF-α was insufficient 
therapeutic response to previous treatments (Table 1). Of note, patient B2 
developed a fourth cranial nerve palsy 6 weeks after stopping colchicine, and 
approximately 8 months after obtaining a genetic diagnosis of DADA2. Treatment 
with adalimumab, high-dose corticosteroids, and 5 mg per kilogram of daily 
aspirin (after excluding intracerebral haemorrhage) resulted in complete 
resolution of his neurological symptoms and normalization of inflammatory 
markers within 7 days. Patient G-2 had a recurrent stroke 2 months after starting 
tocilizumab, prompting the clinician to convert this patient and his sibling (patient 
G-1) to adalimumab. At the time of writing, six months later, both patients remain 
in remission.   
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Identification of CECR1 mutations 
Mutations in CECR1 identified in each subject are shown in Table 1. The 
mutations were initially identified by WES in 4 patients (A-5, B-1, B-2, and C-1). 
Sanger sequencing was performed in first-degree relatives of every patient 
(excluding the parents in family G); and in the extended family members of family 
A, where DNA was available. This revealed 5 subjects with predicted damaging 
homozygous or compound heterozygous CECR1 mutations with minimal or no 
symptoms in family A and C, with age range 4-42 years (Table 1). In family A, the 
homozygous c.752C>T: p.Pro251Leu mutation was identified in the currently 
asymptomatic siblings, the mother, and maternal uncle. In family C, the 
compound heterozygous p.Pro251Leu and c.-114DelC (NM-001282227) 
combination was also identified in one currently asymptomatic sister, whose only 
clinical feature was mild livedo racemosa affecting the palms.  
 
Sanger sequencing was performed in 9 patients with a clinical diagnosis of PAN, 
but with clinical suspicion of DADA2; mutations in CECR1 were identified in 5/9 
of these patients (D, E, F and G-1 & -2).  
 
All identified mutations have been previously described in DADA2 patients (1,2) 
apart from the novel mutation c.144 G→Deletion in patient E causing a frameshift 
and insertion of a premature stop codon. The c.-114DelC (NM-001282227) in 
patients C-1 and C-2 has a prevalence of 4% in the population in the UK 
according to the SP6500 database (4). However, it affects the open reading 
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frame of the mRNA which is highly likely to interfere with protein translation, as 
confirmed by gene expression studies (below). 
 
mRNA expression  
CECR1 mRNA expression in all subjects with DADA2 who were tested with this 
assay (n=8, Table 1) was significantly lower than healthy controls (p value= 
0.0016; figure 2A). CECR1 mRNA expression of healthy adult controls was also 
significantly lower than healthy paediatric controls (p value = 0.0486). Of note, 
mRNA expression was confirmed to be low in subjects C-1 and C-2 who were 
compound heterozygous for the known Pro251Leu mutation, and the c.-114DelC 
variant. 
 
Adenosine deaminase2 enzyme activity assay 
ADA2 enzyme activity assay was measured in plasma from: symptomatic 
DADA2 patients (n=7); asymptomatic DADA2 subjects (n=4); adult carriers of 
CECR1 mutations (n=5); sporadic cPAN patients without CECR1 mutation (n=3; 
3 males, median age 15 years, range 13-17 years); healthy paediatric controls 
(n=22; 13 males; median age 5 years, range 0.3 – 16 years); and healthy adult 
controls (n=20; 8 males, median age 30 years, range 20–44 years).  
 
Results of the ADA2 enzyme activity assay are shown in Figure 2A. DADA2 
subjects (irrespective of symptomatology) had lower ADA2 enzyme activity with 
median of 0.6483 unit/litre (range 0–3.35), compared to healthy paediatric 
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controls (median 10.63 unit/litre, range 1.73–31.45; p<0.0001), and cPAN 
patients without CECR1 mutation (median 9.53 unit/litre, range 5.6-12.4; 
p=0.0108). Enzyme activity in adult carriers was not significantly different from 
healthy adult controls. Healthy paediatric controls had significantly higher 
enzyme activity than healthy adult controls (p< 0.0001; figure 2B). 
 
DISCUSSION 
 
We describe the phenotype and genotype of 15 subjects with DADA2, caused by 
loss of function mutations in CECR1 which encodes for the ADA2 enzyme, 
resulting in an autoinflammatory and vasculopathic syndrome resembling PAN. 
Our series confirms the neurological phenotype of DADA2 described by others 
(Table 2); we also described a similar cutaneous phenotype with the exception of 
erythema nodosum, which we did not observe in our series. One patient had 
coarctation of the aorta; since congenital heart disease is not previously been 
described in DADA2, it remains to be established if this is truly part of the DADA2 
phenotype or not. We emphasize a range of disease severity from limited 
cutaneous vasculitis in some subjects, to severe multi-systemic vasculitis in other 
individuals. One third (5/15) of our cases are currently asymptomatic, never 
having received treatment, at face value a novel finding in our series. The 
phenotypic manifestations of all the DADA2 patients in our series included 
cutaneous vasculitis (including livedo racemosa, ulceration, and ischaemia); 
neurologic involvement (53.3%) and lymphopenia and/or 
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hypogammaglobulinemia (7/15, 46.6%). Four/15 subjects fulfilled classification 
criteria for systemic cPAN (5); 5/15 (33.3%) had an initial clinical diagnosis of 
cutaneous PAN; one patient (subject C1) had an unclassified vasculitis; and 5/15 
(33.3%) were asymptomatic, referred hereafter to as pre-symptomatic DADA2 
(Table 1). Potentially of considerable diagnostic and prognostic importance, 
however, is that all 15 subjects had decreased enzymatic function of serum 
ADA2, and correspondingly low CECR1 mRNA expression.  
 
The 5 pre-symptomatic DADA2 subjects (age range 4-42 years old) were 
detected through screening of relatives of index cases. Four/5 had no evidence 
of systemic inflammation, lymphopenia, or hypogammaglobulinaemia (Table 1); 
data on one case (A-2) were not available regarding these laboratory parameters 
(Table 1). At face value, our description of these 5 asymptomatic cases is novel 
compared to other series; however, Elkan et al (1) have reported patients with 
DADA2 who presented with first symptoms in adulthood (18-59 years old). 
Therefore, with longer follow-up, some of these asymptomatic cases may 
develop symptoms of DADA2. As such, we recommend screening of all 
unaffected siblings of index cases by Sanger sequencing of CECR1, and serum 
ADA2 enzyme activity. From an ethical perspective we suggest that this 
screening approach is warranted since although it is unclear what factors trigger 
development of disease, the first presentation may be severe, disabling, or even 
life-threatening (such as stroke).  
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Pre-symptomatic molecular diagnosis of DADA2 allows early intervention with 
immunosuppression in the event of an acute presentation, and thus satisfies a 
general principle of genetic screening that knowledge of the genetic mutation 
would affect medical management. This indeed was the case for one of our 
series (subject B2) who developed a brain stem stroke and fourth cranial nerve 
palsy 6 weeks after stopping colchicine (Table 1); we rapidly commenced 
adalimumab plus high-dose corticosteroids and aspirin, which resulted in 
complete resolution of his neurological symptoms within 7 days. That said, it may 
be many decades before symptoms develop; pre-symptomatic genetic diagnosis 
of DADA2 during childhood therefore requires careful genetic counselling since 
not all families may elect to have this due to the significant burden of uncertainty 
regarding the prognosis. Since treating all pre-symptomatic patients with lifelong 
anti-TNF-α is ethically challenging, and economically questionable for third party 
payers, we currently recommend close and regular follow up of pre-symptomatic 
subjects. A biomarker to predict disease onset in pre-symptomatic cases is 
clearly urgently needed. 
 
The serum ADA2 enzyme activity in all DADA2 subjects was significantly lower 
than healthy paediatric controls, and sporadic cPAN patients (n=3) without 
CECR1 mutations. Interestingly, the enzyme activity of healthy paediatric 
controls was significantly higher than healthy adult controls, as was CECR1 
mRNA expression (Figure 2). This finding could suggest that ADA2 plays an 
important vaso-protective role in health, particularly-so in the young. One obvious 
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hypothesis to explain that is that ADA2 could act as a modulator of vascular 
inflammation triggered by intercurrent infection, which is much more common in 
the young. Of particular importance in this context was our observation of a lack 
of difference between DADA2 individuals and healthy adult controls; this has 
important practical implications in terms of the reference range used for the 
interpretation of ADA2 activity as a screening test for DADA2. Future work now 
needs to focus on how ADA2 operates at the physiological level in health and in 
ageing, and to properly examine the complex relationship between genotype, 
age, mRNA expression and ADA2 activity. 
 
In our series, 9/10 symptomatic DADA2 patients required treatment with anti-
TNFα; the main indication for this was inadequate therapeutic response to other 
DMARDs, and/or inability to wean corticosteroids. One important 
autoinflammatory feature of DADA2 is skewing towards M1 pro-inflammatory 
macrophages, causing dysregulated pro-inflammatory cytokine secretion 
including TNF-α and interleukin-1β (2). Thus, anti-TNF-α treatment appears to be 
effective, and is a logical choice for DADA2. Although studies in ANCA vasculitis 
favour the use of monoclonal antibodies over etanercept, published experience  
thus far does not obviously suggest that this is true for patients with DADA2, 
since at least 14 patients have received etanercept with seemingly favourable 
results (Table 2; 1,2,6,7). Less is known about IL-6 in DADA2, although 
tocilizumab could also be effective. However, subject G-2 developed a stroke 2 
months after initiation of tocilizumab, and is currently stable on adalimumab. It is 
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unclear what role haematopoietic stem cell transplantation (8), gene therapy, or 
enzyme replacement (for example by regular plasma infusions) (9) might play in 
the treatment for DADA2 in the future. 
 
In summary, we provide a description of the expanding phenotype and genotype 
of DADA2, and emphasise the fact that pre-symptomatic cases also demonstrate 
low levels of ADA2 enzyme activity, comparable to symptomatic DADA2 patients.  
It is currently unclear what triggers the full disease expression. We speculate that 
possible precipitating factors such as infection and/or other environmental 
influences could trigger disease expression. We have established tentative 
normative ranges for adult and paediatric ADA2 function, but we suggest there is 
a need for a much larger normative dataset for children and adults for this to be 
used with confidence as a screening test for DADA2. Whilst we provide age-
related reference ranges for ADA2 enzyme activity, our data are too limited to 
provide didactic recommendations regarding screening strategies for this rare 
monogenic autoinflammatory disease. That said we recommend considering 
genetic screening and ADA2 enzyme activity in patients with familial vasculitis, 
recalcitrant PAN, and early-onset PAN-like disease (under age of 5 years). 
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 Table 1 Summary of clinical characteristics, treatment and genotype of 15 DADA2 patients 
 
Patient Sex/ 
Ethnicity 
Initial Clinical 
Diagnosis 
Age at 
genetic 
diagnosis 
(years) 
Age at 
disease 
onset 
(years) 
Highest 
CRP (mg/L) 
(normal <5) 
Neurological 
involvement 
Cutaneous 
involvement 
Other features Previous 
Treatments** 
Current  
Pred 
dose 
(mg/kg) 
Current 
Treatment (s) 
CECR1 mutation (s) mRNA 
expression 
tested 
A-1 F/ 
Iraqi 
Asymptomatic 42 NA  8 NA NA No systemic 
inflammation, 
No lymphopaenia, 
Normal Igs 
 NA   NA Nil Hom. c.752C>T: 
p.Pro251Leu 
Y 
A-2 M/ 
Iraqi 
Asymptomatic 34 NA Not yet 
tested  
NA NA Not yet tested   NA   NA Nil Hom. c.752C>T: 
p.Pro251Leu 
N 
A-3 M/ 
Iraqi 
Cutaneous PAN 19 10 12 ┼Lower limb 
#UMN signs 
Livedo 
racemosa 
No Colchicine Nil Nil Hom. c.752C>T: 
p.Pro251Leu 
Y 
A-4 M/ 
Iraqi 
Asymptomatic 17 NA  <1 NA NA No systemic 
inflammation, 
No lymphopaenia, 
Normal Igs 
  NA  NA  Nil Hom. c.752C>T: 
p.Pro251Leu 
N 
A-5 M/ 
Iraqi 
PAN 15 3 62 Axonal 
polyneuropathy 
Livedo 
racemosa, 
Peripheral 
Ischaemia 
Lymphopaenia 
low IgG 
IV CYC , Pred 1 
mg/kg/day 
Nil AZA, infliximab, 
Aspirin 
Hom. c.752C>T: 
p.Pro251Leu 
Y 
A-6 F/ 
Iraqi 
Asymptomatic 4 NA <5 NA NA No systemic 
inflammation, 
No lymphopaenia, 
Normal Igs 
  NA  NA  Nil Hom. c.752C>T: 
p.Pro251Leu 
N 
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B-1 F/ 
Indian 
Cutaneous PAN 8 5 17 No Livedo 
racemosa, 
Nodular rash  
♥Systemic 
inflammation  
Colchicine Nil  Adalimumab Hom. c.139G>C: 
p.Gly47Arg 
Y 
B-2* M/ 
Indian 
Cutaneous PAN 6 5 24 *Brain stem 
stroke  
Livedo 
racemosa, 
Nodular rash 
♥Systemic 
inflammation 
Colchicine 1 Adalimumab, 
aspirin 
Hom. c.139G>C: 
p.Gly47Arg 
Y 
C-1 M/ 
Caucasian 
Unclassified 
vasculitis 
16 10 15 No Peripheral 
ischaemia; 
livedo 
racemosa 
Low IgM 
Coarctation of 
aorta  
Nil 0.25 Adalimumab, 
aspirin 
Compound het.  
c.752C>T: 
p.Pro251Leu  
and c.-114DelC 
Y 
C-2 F/ 
Caucasian 
Asymptomatic 5 5 5 NA Mild livedo 
racemosa of 
the palms 
No systemic 
inflammation, 
No lymphopenia, 
Normal Igs 
Nil Nil Nil Compound het.  
c.752C>T: 
p.Pro251Leu 
 and c.-114DelC 
Y 
D M/ 
Caucasian 
PAN 22 2 36 Intracerebral 
haemorrhage 
Livedo 
racemosa 
Low IgG, 
Lymphopenia 
Hypertension right 
optic nerve atrophy  
Pred 2 mg/kg/day, 
 IV CYC  
0.25 AZA 1 
mg/kg/day, 
IVIG; 
Infliximab, 
Aspirin 
Compound het. 
 c.2T>c and  
c.506 C>T: p. 
Arg169Gln 
N 
E F/ 
Caucasian 
PAN 11 6 67 Brain stem 
stroke 
Livedo 
racemosa 
Low IgG, 
Lymphopenia 
Hypertension  
Pred 0.5 
mg/kg/day, IV CYC  
followed by  
AZA 2 mg/kg/day, 
MMF, Rituximab 
Nil AZA 2 
mg/kg/day,  
Infliximab, 
Aspirin 
Compound het. 
 c.2T>C and  
c.144delG: 
p.Arg49GlyfsX4 
N 
F F/ 
Caucasian 
PAN 24 6 26 Intracerebral 
haemorrhage 
Peripheral 
ischaemia; 
livedo 
racemosa 
Lymphopenia, 
Hypertension, 
Reno-vascular 
arterial aneurysms  
Pred 
0.5mg/kg/day, IV 
CYC  followed by 
 AZA 2 mg/kg/day 
Nil MMF 25 
mg/kg/day 
/Infliximab 
Compound het.  
c.506C>T: 
p.Arg169Gln  
and c.1358A>G: 
p.Tyr453Cys 
N 
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G-1 M/ 
Caucasian 
PAN 11 3 32 Basal ganglia 
stroke 
Livedo 
racemosa 
Lymphopenia, Low 
IgM, ♥Systemic 
inflammation 
Pred 2 mg/kg/day, 
AZA, MTX 
Tocilizumab 
Nil Adalimumab Hom. c.506C>T: 
p.Arg169Gln 
N 
G-2 M/ 
Caucasian 
PAN 12 5 15 Intracerebral 
haemorrhage  
Livedo 
racemosa 
Lymphopenia, Low 
IgM, ♥Systemic 
inflammation 
Pred 2 mg/kg/day, 
IV CYC 
Tocilizumab 
Nil Adalimumab Hom. c.506C>T: 
p.Arg169Gln 
N 
 
 
Patients from the same family are grouped by letter. *Patient B2 developed 4th cranial nerve palsy 6 weeks after stopping colchicine, and 
approximately 8 months after obtaining a genetic diagnosis of DADA2. Treatment with adalimumab, high-dose corticosteroids, and 5 mg per kilogram of daily 
aspirin resulted in complete resolution of his neurological symptoms and normalization of inflammatory markers within 7 days. Patient G-2 had a recurrent stroke 
on tocilizumab, prompting the clinician to convert this patient and their sibling (patient G-1) to adalimumab. **All of these treatments failed to control the disease 
adequately. ♥Systemic inflammation: persistently elevated ESR, CRP, and Serum amyloid A. #UMN: upper motor neurone (┼brisk ankle reflexes, excessive ankle 
clonus, but normal brain and spinal cord imaging); AZA: azathioprine, CRP: C reactive protein, CYC: cyclophosphamide, DADA2: deficiency of adenosine 
deaminase 2, ESR: erythrocyte sedimentation rate, F: female, Het: heterozygous, Hom: homozygous, IV: intravenous, M: male, Mg/kg/day: milligram/kilogram/day, 
MMF: mycophenolate mofetil, NA: not applicable, PAN: polyarteritis nodosa, Pred: prednisolone.  
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Our series 
(N=15) 
Zhou et al
2
 
(N=9) 
Elkan et al
1  
(N=24) 
Batu et al
7
 
(N=6) 
Clinical manifestations N (%) 
Neurological involvement (total) 8 (53.3) 9 (100) 15 (62.5) 3 (50.0) 
     Central nervous system  6 (40.0) 9 (100) 5 (20.8) 3 (50.0) 
- Intracerebral haemorrhage 3 (20.0) 3 (33.3) 1 (4.2) NR 
- Stroke 3 (20.0) 8 (88.9) 5 (20.8) 3 (50.0) 
    Peripheral nervous system  2 (13.3) NR 10 (41.7) NR 
Cutaneous involvement (total) 11 (73.3) 8 (88.9) 16 (66.7) 6 (100.0) 
    Livedo racemosa 11 (73.3) 8 (88.9) 16 (66.7) 5 (83.3) 
    Peripheral Ischaemia 3 (20.0) NR 5 (20.8) 2 (33.3) 
    Erythema nodosum 0 (0) 2 (22.2) 1 (4.2) 4 (66.7) 
Immunological involvement 7 (46.6) 5 (55.6) NR 2 (33.3) 
    Lymphopaenia 6 (40.0) 0 (0) NR NR 
    Hypoglobulinaemia 6 (40.0) 5 (55.6) NR 2 (33.3) 
Gastrointestinal involvement 4 (26.7) 8 (88.9) 7 (29.2) 6 
Renal involvement 1 (6.6) 2 (22.2) 7 (29.2) 1 (16.7) 
    Hypertension 3 (20.0) 1 (11.1) 7 (29.2) NR 
Ophthalmologic involvement 1 (6.6) 5 (55.6) NR 3 (50.0) 
Asymptomatic 5 (33.3) 0 (0) 0 (0) 0 (0) 
Congenital heart disease  1 (6.6) NR NR NR 
Treatment with Anti-TNF 9 6 10 3 
    Etanercept 0 6 5 3 
    Infliximab 4 0 2 0 
    Adalimumab 5 0 3 0 
 
Table 2: Clinical features and anti-TNF treatment received by our series and 3 other published series (containing >3 
cases). NR: not reported. 
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Figure legends 
Figure 1 A: Family pedigree and summary of sequenced genotype of p.P251 on 
CECR1 gene in the extended family A. All genotypes identified by Sanger 
sequencing. WT, wild type; P251L/WT is heterozygous variant and P251L/P251L 
is homozygous mutation. B: digital subtraction angiogram of left kidney of patient 
F shows multiple aneurysmal dilatations, and other caliber variation of the 
medium-small intra-renal arteries, C: computer tomography of brain of patient F 
revealing intracerebral haemorrhage. Formal catheter cerebral arteriography (not 
shown) did not reveal any abnormality, consistent with lacunar (small vessel) 
haemorrhagic stroke. D: Livedo racemosa in subject C1 and E. lower limb ulcer 
in subject C1. 
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Figure 2 A: CECR1 mRNA expression was reduced in 7 children and 1 adult 
(asymptomatic) with DADA2 compared with 2 healthy paediatric (p=0.016) and 4 
healthy adult controls B: The adenosine deaminase 2 enzyme activity was 
reduced in 11 patients with DADA2 compared to 22 healthy paediatric controls 
(p<0.0001) and 3 children with sporadic PAN (CECR1 wild-type, p=0.01); there 
was no significant difference between adult carriers and healthy adult controls 
(p=0.2390). Healthy paediatric controls had significantly higher enzyme activity 
than healthy adult controls (p< 0.0001)  
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